1-deoxy-1-morpholinofructose profile

1-Deoxy-1-morpholinofructose (DMF) is a synthetic analog of fructose, a simple sugar. It differs from fructose by having a morpholine ring replacing the hydroxyl group at the C1 position. This modification makes DMF a **potent inhibitor of aldose reductase**, an enzyme responsible for reducing glucose to sorbitol.

Here's why DMF is important for research:

* **Diabetes and diabetic complications:** Elevated glucose levels in diabetes lead to increased sorbitol production by aldose reductase. This accumulation of sorbitol can cause osmotic stress, leading to damage in various tissues, particularly the eyes, kidneys, and nerves. DMF's inhibition of aldose reductase can potentially prevent these complications.
* **Neuropathic pain:** Aldose reductase is also involved in the development of neuropathic pain, a type of chronic pain associated with nerve damage. DMF's inhibitory activity on aldose reductase makes it a potential therapeutic agent for managing neuropathic pain.
* **Other potential applications:** DMF has shown promise in treating various conditions, including cataracts, diabetic retinopathy, and even Alzheimer's disease. It is also being investigated for its potential to reduce oxidative stress and inflammation.

**However, it is important to note that DMF is currently in preclinical development and has not been approved for human use.** More research is needed to assess its safety and efficacy for therapeutic purposes.

Here are some additional points to consider:

* DMF's mechanism of action is not fully understood, and further research is needed to elucidate its complete pharmacological profile.
* DMF's potential side effects are still being investigated, and long-term safety data is limited.
* Although DMF has shown promising results in preclinical studies, its effectiveness in humans is yet to be proven.

Overall, 1-Deoxy-1-morpholinofructose (DMF) is a promising compound with potential therapeutic applications in various diseases, particularly those related to aldose reductase activity. However, further research is necessary to fully understand its safety and efficacy before it can be considered for clinical use.

ID Source	ID
PubMed CID	6454484
SCHEMBL ID	8098959
MeSH ID	M0130883

Synonym
1-dmf
(3s,4r,5r)-1,3,4,5,6-pentahydroxy-1-morpholin-4-ylhexan-2-one
1-deoxy-1-morpholinofructose
ai3-18907
d-fructose, 1-deoxy-1-(4-morpholinyl)-
SCHEMBL8098959
morpholino-fructose
1-c-morpholin-4-ylhex-2-ulose
DTXSID50978700

Excerpt	Relevance	Reference
" The selection of serum albumin and the concentration used in the standard solutions is critical since the dose-response curve is affected differently and will therefore influence the estimated values."	( The estimation of serum fructosamine: an alternative measurement to glycated haemoglobin. Gatt, JA; Hindle, EJ; Rostron, GM, 1985)	0.27

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	9 (47.37)	18.7374
1990's	1 (5.26)	18.2507
2000's	7 (36.84)	29.6817
2010's	2 (10.53)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	1.98	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
uric acid Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.	2.01	1	uric acid	Escherichia coli metabolite; human metabolite; mouse metabolite
iodoacetamide [no description available]	2.01	1
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.02	1	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.	2.42	2	aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid	algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.51	2	pyrrole; secondary amine
nitroblue tetrazolium Nitroblue Tetrazolium: Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease.	3.07	5	organic cation
fructosamine Fructosamine: An amino sugar formed when glucose non-enzymatically reacts with the N-terminal amino group of proteins. The fructose moiety is derived from glucose by the classical Amadori rearrangement.	3.84	12
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.17	1	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
fructose 3-phosphate fructose 3-phosphate: found in the lens of diabetic rats; RN given is for D-fructose-3-phosphate without isomeric designation	2	1
D-fructopyranose [no description available]	4.29	19	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
fructosyl-lysine fructosyllysine : A glyco-amino acid consisting of a D-fructosyl residue attached to the epsilon-amino group of L-lysine.	2.01	1	fructosamine; glyco-amino acid	Escherichia coli metabolite
cs 0777 CS 0777: a sphingosine-1-phosphate receptor modulator	2.51	2
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	2.02	1

Condition	Relationship Strength	Studies
Hyperlipemia [description not available]	2.01	1
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	2.89	4
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.01	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.96	1

1-deoxy-1-morpholinofructose

Cross-References

Synonyms (9)

Research Excerpts

Dosage Studied

Research

Studies (19)

Study Types